These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18393323)

  • 1. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain?
    Charlton M
    Hepatology; 2008 May; 47(5):1431-3. PubMed ID: 18393323
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease: what are the odds your patient will get a transplant?
    Leverage SC; Angulo P
    Clin Gastroenterol Hepatol; 2011 Aug; 9(8):631-2. PubMed ID: 21683162
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease.
    Duseja A; Sharma B; Kumar A; Kapil S; Das A; Dhiman RK; Chawla YK
    Hepatology; 2010 Dec; 52(6):2248-9. PubMed ID: 20725907
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease in pediatric patients.
    Sinatra FR
    JPEN J Parenter Enteral Nutr; 2012 Jan; 36(1 Suppl):43S-8S. PubMed ID: 22237875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
    Kluwe J; Lohse AW
    Internist (Berl); 2005 Dec; 46(12):1324-30. PubMed ID: 16247633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.
    Friedman SL
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):71-2. PubMed ID: 23296246
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease: A Silent Epidemic.
    Sivell C
    Gastroenterol Nurs; 2019; 42(5):428-434. PubMed ID: 31574071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NASH-related liver failure: one hit too many?
    Day CP
    Am J Gastroenterol; 2002 Aug; 97(8):1872-4. PubMed ID: 12190148
    [No Abstract]   [Full Text] [Related]  

  • 10. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease.
    Porepa L; Ray JG; Sanchez-Romeu P; Booth GL
    CMAJ; 2010 Aug; 182(11):E526-31. PubMed ID: 20566726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus and nonalcoholic Fatty liver disease: similar risk factors for necroinflammation, fibrosis, and cirrhosis.
    Comparcola D; Alisi A; Nobili V
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):97; author reply 97. PubMed ID: 19772950
    [No Abstract]   [Full Text] [Related]  

  • 12. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease.
    Ong JP; Younossi ZM
    Clin Liver Dis; 2005 Nov; 9(4):617-34, vi. PubMed ID: 16207567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.
    Bugianesi E; Vanni E; Marchesini G
    Curr Diab Rep; 2007 Jun; 7(3):175-80. PubMed ID: 17547834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body composition and hepatic steatosis as precursors for fibrotic liver disease.
    McCullough AJ; Falck-Ytter Y
    Hepatology; 1999 Apr; 29(4):1328-30. PubMed ID: 10094983
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease in pediatric patients--a problem that is "enormous" and "growing"!
    Rosenthal P
    JPEN J Parenter Enteral Nutr; 2012 Jan; 36(1 Suppl):7S-8S. PubMed ID: 22237882
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation.
    Cauble MS; Gilroy R; Sorrell MF; Mailliard ME; Sudan DL; Anderson JC; Wisecarver JL; Balakrishnan S; Larsen JL
    Transplantation; 2001 Apr; 71(7):892-5. PubMed ID: 11349722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation.
    Heidelbaugh JJ; Bruderly M
    Am Fam Physician; 2006 Sep; 74(5):756-62. PubMed ID: 16970019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
    Serfaty L; Lemoine M
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based screening programs for nonalcoholic fatty liver disease in youth and clues to prevention.
    Manco M
    J Clin Endocrinol Metab; 2014 Mar; 99(3):774-6. PubMed ID: 24823704
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease in Asia: a story of growth.
    Wong VW
    J Gastroenterol Hepatol; 2013 Jan; 28(1):18-23. PubMed ID: 23094755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.